Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides

Author(s): L. Auzzas, F. Zanardi, L. Battistini, P. Burreddu, P. Carta, G. Rassu, C. Curti, G. Casiraghi.

Journal Name: Current Medicinal Chemistry

Volume 17 , Issue 13 , 2010

Submit Manuscript
Submit Proposal

Abstract:

The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-ofconcept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing αvβ3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.

Keywords: Integrins, design of RGD ligands, cancer therapy and imaging, targeted drug delivery, multimodality, integrin targeted nanoparticles

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 13
Year: 2010
Page: [1255 - 1299]
Pages: 45
DOI: 10.2174/092986710790936301
Price: $58

Article Metrics

PDF: 19